$KYTX News

Kyverna Therapeutics Presents Updated Results From Its Phase 1 Trial Of CD-19 Directed CAR T-Cell Therapy In Progressive Multiple Sclerosis At MS Toronto 2026

Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto

Kyverna Therapeutics To Present Full One-Year Data Set From KYSA-8, Registrational Trial Of Miv-Cel In Patients With Stiff Person Syndrome, At MS Toronto 2026, Joint ACTRIMS-ECTRIMS Meeting

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

Kyverna Therapeutics To Demonstrate Two Abstracts For Presentation At MSToronto2026 10th Joint ACTRIMS-ECTRIMS Meeting

KYTX Stock Reverses Gains After One-Year Cell Therapy Trial Data — But CEO Says Disease Burden Justifies A Premium Price

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials - Slideshow

Kyverna stock jumps on positive one-year therapy data

Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript

Kyverna Therapeutics Therapy Delivers Sustained Relief in Rare Neurological Conditions

Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials

Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis

Kyverna Therapeutics Announces One-year Topline Data From KYSA-8, Its Trial Of Miv-Cel In Patients With Stiff Person Syndrome, And Topline Longer-Term Follow-up Data From Phase 2 Of KYSA-6, Its Trial In Patients With Generalized Myasthenia Gravis; Topline Durability Data Reinforce Potential For Single-dose Miv-Cel To Free Patients From Lifelong Disease Burden And Chronic Immunotherapies, Further Highlighting Miv-Cel’s Differentiated Construct

Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Kyverna Therapeutics to Present at Upcoming Investor Conferences

Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval

Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results

Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate

Kyverna Therapeutics: 'Strong Buy' On ElevateBio Manufacturing Deal And RA Program Advancement

Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel